The results of nearly all recent observational studies of patients from around the world diagnosed with COVID-19 show no association between exposure to NSAIDs (including ibuprofen) and worsening clinical outcomes.
CHPA is rebranding its identity for the first time in 20 years. The rebranding effort has resulted in a new logo, tagline, and brand narrative following the addition of consumer medical devices to its scope of representation.
CHPA, its educational foundation, and member companies are empowering consumers to practice responsible self-care, providing resources to help respond to this pandemic. We’re guided by these core principles.
On behalf of the Consumer Healthcare Products Association, enclosed herein are comments on the 2019 revised draft guidance document as well as FDA’s decision to revoke CPG 400.400.
There is currently no clinical data indicating that dextromethorphan has a pro-viral effect in people with COVID-19 infection. The study results published in Nature are experimental, preliminary, and not conclusive.
The U.S. dietary supplement industry commends FDA for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19.
